<p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）在週六發佈給投資者的研究報告中，被華爾街 Zen 的分析師將評級從 “持有” 下調至 “賣出”。</p>
<p>獲取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 MIRA Pharmaceuticals 股票的 “賣出（e+）” 評級。根據 MarketBeat 的數據，一位研究分析師對該股票給予了賣出評級，該公司的平均評級為 “賣出”。</p>
<p><strong>閲讀我們關於 MIRA 的最新股票報告</strong></p>
<h2>MIRA Pharmaceuticals 價格表現</h2>
<p>MIRA 股票在週五開盤價為 1.39 美元。該公司的市值為 5821 萬美元，市盈率為-0.91，貝塔值為 1.72。公司 50 日移動平均線為 1.42 美元，200 日移動平均線為 1.40 美元。MIRA Pharmaceuticals 的 52 周最低價為 0.73 美元，52 周最高價為 2.45 美元。</p>
<p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）最後一次發佈季度收益數據是在 11 月 13 日星期四。該公司報告本季度每股收益為（1.18 美元），低於市場共識預期的（0.11 美元）1.07 美元。股票分析師預計 MIRA Pharmaceuticals 在當前財政年度將發佈-0.6 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>大型投資者最近調整了對該公司的持股。國際資產投資管理公司在第二季度收購了 MIRA Pharmaceuticals 的新股份，價值 42,000 美元。Two Sigma Investments LP 在第三季度將其在 MIRA Pharmaceuticals 的持股提高了 129.8%。Two Sigma Investments LP 目前擁有 45,703 股該公司的股票，價值 62,000 美元，此前在該期間額外收購了 25,816 股。XTX Topco Ltd 在第二季度收購了 MIRA Pharmaceuticals 的新股份，價值約 26,000 美元。Creative Planning 在第二季度購買了 MIRA Pharmaceuticals 的新股份，價值約 27,000 美元。最後，First American Bank 在第三季度將其在 MIRA Pharmaceuticals 的持股提高了 150.0%。First American Bank 目前擁有 50,000 股該公司的股票，價值 68,000 美元，此前在上個季度額外購買了 30,000 股。目前，35.16% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 MIRA Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>MIRA Pharmaceuticals, Inc 是一家處於臨牀前階段的製藥開發公司，擁有兩個神經科學項目，針對一系列神經和精神疾病。該公司擁有 Ketamir-2 的美國、加拿大和墨西哥獨佔權，這是一種正在研究的口服氯胺酮類似物，旨在為抗藥性抑鬱症、伴有自殺意念的重度抑鬱症和創傷後應激障礙患者提供超快速的抗抑鬱效果。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，而不是 MIRA Pharmaceuticals</li>
<li>如何在購買前評估一隻股票</li>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>如何利用分析師評級進行交易</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>3 只可以幫助應對通貨膨脹的食品雜貨股票</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MIRA Pharmaceuticals 嗎？</h2>
<p>在考慮 MIRA Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MIRA Pharmaceuticals 並不在名單上。</p>
<p>雖然 MIRA Pharmaceuticals 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MIRA

<p>Wall Street Zen 將 MIRA Pharmaceuticals (NASDAQ:MIRA) 的評級從 “持有” 下調至 “賣出”。Weiss Ratings 也重申了 “賣出” 評級。MIRA 的股票開盤價為 1.39 美元，市值為 5821 萬美元。分析師預計該財年的每股收益為 -0.6。機構投資者已調整其持股比例，機構持股佔比為 35.16%。MIRA 作為一家處於臨牀前階段的製藥公司，專注於神經系統疾病。儘管評級為賣出，分析師建議其他股票作為更好的投資選擇</p>

<p>MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) was downgraded by analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）在週六發佈給投資者的研究報告中，被華爾街 Zen 的分析師將評級從 “持有” 下調至 “賣出”。</p>
</div><p>Get <strong>MIRA Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of MIRA Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 MIRA Pharmaceuticals 股票的 “賣出（e+）” 評級。根據 MarketBeat 的數據，一位研究分析師對該股票給予了賣出評級，該公司的平均評級為 “賣出”。</p>
</div><p><strong>Read Our Latest Stock Report on MIRA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 MIRA 的最新股票報告</strong></p>
</div><h2>MIRA Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>MIRA Pharmaceuticals 價格表現</h2>
</div><p>MIRA stock opened at $1.39 on Friday. The stock has a market capitalization of $58.21 million, a price-to-earnings ratio of -0.91 and a beta of 1.72. The company has a 50-day moving average of $1.42 and a two-hundred day moving average of $1.40. MIRA Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $2.45.</p>
<div class="lb-trans"><p>MIRA 股票在週五開盤價為 1.39 美元。該公司的市值為 5821 萬美元，市盈率為-0.91，貝塔值為 1.72。公司 50 日移動平均線為 1.42 美元，200 日移動平均線為 1.40 美元。MIRA Pharmaceuticals 的 52 周最低價為 0.73 美元，52 周最高價為 2.45 美元。</p>
</div><p>MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Equities analysts expect that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）最後一次發佈季度收益數據是在 11 月 13 日星期四。該公司報告本季度每股收益為（1.18 美元），低於市場共識預期的（0.11 美元）1.07 美元。股票分析師預計 MIRA Pharmaceuticals 在當前財政年度將發佈-0.6 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in MIRA Pharmaceuticals during the second quarter worth $42,000. Two Sigma Investments LP lifted its holdings in shares of MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company's stock worth $62,000 after acquiring an additional 25,816 shares during the period. XTX Topco Ltd acquired a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter valued at about $26,000. Creative Planning bought a new stake in MIRA Pharmaceuticals in the second quarter valued at about $27,000. Finally, First American Bank raised its position in MIRA Pharmaceuticals by 150.0% in the third quarter. First American Bank now owns 50,000 shares of the company's stock worth $68,000 after purchasing an additional 30,000 shares in the last quarter. 35.16% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該公司的持股。國際資產投資管理公司在第二季度收購了 MIRA Pharmaceuticals 的新股份，價值 42,000 美元。Two Sigma Investments LP 在第三季度將其在 MIRA Pharmaceuticals 的持股提高了 129.8%。Two Sigma Investments LP 目前擁有 45,703 股該公司的股票，價值 62,000 美元，此前在該期間額外收購了 25,816 股。XTX Topco Ltd 在第二季度收購了 MIRA Pharmaceuticals 的新股份，價值約 26,000 美元。Creative Planning 在第二季度購買了 MIRA Pharmaceuticals 的新股份，價值約 27,000 美元。最後，First American Bank 在第三季度將其在 MIRA Pharmaceuticals 的持股提高了 150.0%。First American Bank 目前擁有 50,000 股該公司的股票，價值 68,000 美元，此前在上個季度額外購買了 30,000 股。目前，35.16% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About MIRA Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 MIRA Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals, Inc 是一家處於臨牀前階段的製藥開發公司，擁有兩個神經科學項目，針對一系列神經和精神疾病。該公司擁有 Ketamir-2 的美國、加拿大和墨西哥獨佔權，這是一種正在研究的口服氯胺酮類似物，旨在為抗藥性抑鬱症、伴有自殺意念的重度抑鬱症和創傷後應激障礙患者提供超快速的抗抑鬱效果。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than MIRA Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How to trade using analyst ratings</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 MIRA Pharmaceuticals</li>
<li>如何在購買前評估一隻股票</li>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>如何利用分析師評級進行交易</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>3 只可以幫助應對通貨膨脹的食品雜貨股票</li>
<li>Palo Alto Networks 股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MIRA Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MIRA Pharmaceuticals 嗎？</h2>
</div><p>Before you consider MIRA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MIRA Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MIRA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MIRA Pharmaceuticals 並不在名單上。</p>
</div><p>While MIRA Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MIRA Pharmaceuticals 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MIRA Pharmaceuticals（納斯達克代碼：MIRA）在 Wall Street Zen 的評級被下調至賣出